Prostate cancer radiotherapy dose response

An update of the Fox Chase experience

Alan Pollack, Alexandra L. Hanlon, Eric M. Horwitz, Steven J. Feigenberg, Robert G. Uzzo, Gerald E. Hanks

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Purpose: The effectiveness of increasing radiotherapy dose for men with prostate cancer was evaluated with reference to prognostic groups as defined by pretreatment serum prostate specific antigen (PSA), Gleason score, T stage and perineural invasion. Materials and Methods: There were 839 men treated between April 1989 and December 1997 with conformal radiotherapy alone. Cox multivariate analysis was used to establish important predictors of biochemical failure (BF) separately for patients with an initial pretreatment PSA (iPSA) of less than 10, 10 to 19.9, or 20 or greater ng/ml. Radiotherapy (RT) dose was evaluated as a continuous and categorical (dose groups of less than 72, 72 to 75.9 and 76 Gy or greater) variable. Results: At a median 63-month followup multivariate analysis demonstrated that iPSA and radiotherapy (RP) dose were the most significant predictors of BF, followed by Gleason score and T stage. Perineural invasion was not an independent correlate of outcome. RT dose was significant in all iPSA groups (less than 10, 10 to 19.9 and 20 or greater ng/ml). Gleason score was significant when iPSA was less than 10 ng/ml. T stage was significant when iPSA was 20 ng/ml or greater and it was borderline when iPSA was 10 to 19.9 ng/ml (p = 0.08). Prognostic subgroups were derived from these results and tested for an effect of RT dose on univariate analysis. Radiation dose was not a correlate of BF in the most favorable (PSA less than 10 ng/ml and Gleason score 2 to 6) and the most unfavorable (PSA 20 ng/ml or greater and stage T3-T4) prognostic groups but it was otherwise an influential determinant of outcome. Conclusions: RT dose escalation to 76 Gy or greater improved patient outcome for all prognostic groups except those at the favorable and unfavorable extremes.

Original languageEnglish
Pages (from-to)1132-1136
Number of pages5
JournalJournal of Urology
Volume171
Issue number3
DOIs
StatePublished - Mar 1 2004
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Radiotherapy
Neoplasm Grading
Prostate-Specific Antigen
Multivariate Analysis
Conformal Radiotherapy
Radiation
Serum

Keywords

  • Dose-response relationship, radiation
  • Prostate
  • Prostatic neoplasms
  • Radiotherapy

ASJC Scopus subject areas

  • Urology

Cite this

Pollack, A., Hanlon, A. L., Horwitz, E. M., Feigenberg, S. J., Uzzo, R. G., & Hanks, G. E. (2004). Prostate cancer radiotherapy dose response: An update of the Fox Chase experience. Journal of Urology, 171(3), 1132-1136. https://doi.org/10.1097/01.ju.0000111844.95024.74

Prostate cancer radiotherapy dose response : An update of the Fox Chase experience. / Pollack, Alan; Hanlon, Alexandra L.; Horwitz, Eric M.; Feigenberg, Steven J.; Uzzo, Robert G.; Hanks, Gerald E.

In: Journal of Urology, Vol. 171, No. 3, 01.03.2004, p. 1132-1136.

Research output: Contribution to journalArticle

Pollack, A, Hanlon, AL, Horwitz, EM, Feigenberg, SJ, Uzzo, RG & Hanks, GE 2004, 'Prostate cancer radiotherapy dose response: An update of the Fox Chase experience', Journal of Urology, vol. 171, no. 3, pp. 1132-1136. https://doi.org/10.1097/01.ju.0000111844.95024.74
Pollack, Alan ; Hanlon, Alexandra L. ; Horwitz, Eric M. ; Feigenberg, Steven J. ; Uzzo, Robert G. ; Hanks, Gerald E. / Prostate cancer radiotherapy dose response : An update of the Fox Chase experience. In: Journal of Urology. 2004 ; Vol. 171, No. 3. pp. 1132-1136.
@article{e30f06670b0246e9b8556562f8b072ec,
title = "Prostate cancer radiotherapy dose response: An update of the Fox Chase experience",
abstract = "Purpose: The effectiveness of increasing radiotherapy dose for men with prostate cancer was evaluated with reference to prognostic groups as defined by pretreatment serum prostate specific antigen (PSA), Gleason score, T stage and perineural invasion. Materials and Methods: There were 839 men treated between April 1989 and December 1997 with conformal radiotherapy alone. Cox multivariate analysis was used to establish important predictors of biochemical failure (BF) separately for patients with an initial pretreatment PSA (iPSA) of less than 10, 10 to 19.9, or 20 or greater ng/ml. Radiotherapy (RT) dose was evaluated as a continuous and categorical (dose groups of less than 72, 72 to 75.9 and 76 Gy or greater) variable. Results: At a median 63-month followup multivariate analysis demonstrated that iPSA and radiotherapy (RP) dose were the most significant predictors of BF, followed by Gleason score and T stage. Perineural invasion was not an independent correlate of outcome. RT dose was significant in all iPSA groups (less than 10, 10 to 19.9 and 20 or greater ng/ml). Gleason score was significant when iPSA was less than 10 ng/ml. T stage was significant when iPSA was 20 ng/ml or greater and it was borderline when iPSA was 10 to 19.9 ng/ml (p = 0.08). Prognostic subgroups were derived from these results and tested for an effect of RT dose on univariate analysis. Radiation dose was not a correlate of BF in the most favorable (PSA less than 10 ng/ml and Gleason score 2 to 6) and the most unfavorable (PSA 20 ng/ml or greater and stage T3-T4) prognostic groups but it was otherwise an influential determinant of outcome. Conclusions: RT dose escalation to 76 Gy or greater improved patient outcome for all prognostic groups except those at the favorable and unfavorable extremes.",
keywords = "Dose-response relationship, radiation, Prostate, Prostatic neoplasms, Radiotherapy",
author = "Alan Pollack and Hanlon, {Alexandra L.} and Horwitz, {Eric M.} and Feigenberg, {Steven J.} and Uzzo, {Robert G.} and Hanks, {Gerald E.}",
year = "2004",
month = "3",
day = "1",
doi = "10.1097/01.ju.0000111844.95024.74",
language = "English",
volume = "171",
pages = "1132--1136",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Prostate cancer radiotherapy dose response

T2 - An update of the Fox Chase experience

AU - Pollack, Alan

AU - Hanlon, Alexandra L.

AU - Horwitz, Eric M.

AU - Feigenberg, Steven J.

AU - Uzzo, Robert G.

AU - Hanks, Gerald E.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Purpose: The effectiveness of increasing radiotherapy dose for men with prostate cancer was evaluated with reference to prognostic groups as defined by pretreatment serum prostate specific antigen (PSA), Gleason score, T stage and perineural invasion. Materials and Methods: There were 839 men treated between April 1989 and December 1997 with conformal radiotherapy alone. Cox multivariate analysis was used to establish important predictors of biochemical failure (BF) separately for patients with an initial pretreatment PSA (iPSA) of less than 10, 10 to 19.9, or 20 or greater ng/ml. Radiotherapy (RT) dose was evaluated as a continuous and categorical (dose groups of less than 72, 72 to 75.9 and 76 Gy or greater) variable. Results: At a median 63-month followup multivariate analysis demonstrated that iPSA and radiotherapy (RP) dose were the most significant predictors of BF, followed by Gleason score and T stage. Perineural invasion was not an independent correlate of outcome. RT dose was significant in all iPSA groups (less than 10, 10 to 19.9 and 20 or greater ng/ml). Gleason score was significant when iPSA was less than 10 ng/ml. T stage was significant when iPSA was 20 ng/ml or greater and it was borderline when iPSA was 10 to 19.9 ng/ml (p = 0.08). Prognostic subgroups were derived from these results and tested for an effect of RT dose on univariate analysis. Radiation dose was not a correlate of BF in the most favorable (PSA less than 10 ng/ml and Gleason score 2 to 6) and the most unfavorable (PSA 20 ng/ml or greater and stage T3-T4) prognostic groups but it was otherwise an influential determinant of outcome. Conclusions: RT dose escalation to 76 Gy or greater improved patient outcome for all prognostic groups except those at the favorable and unfavorable extremes.

AB - Purpose: The effectiveness of increasing radiotherapy dose for men with prostate cancer was evaluated with reference to prognostic groups as defined by pretreatment serum prostate specific antigen (PSA), Gleason score, T stage and perineural invasion. Materials and Methods: There were 839 men treated between April 1989 and December 1997 with conformal radiotherapy alone. Cox multivariate analysis was used to establish important predictors of biochemical failure (BF) separately for patients with an initial pretreatment PSA (iPSA) of less than 10, 10 to 19.9, or 20 or greater ng/ml. Radiotherapy (RT) dose was evaluated as a continuous and categorical (dose groups of less than 72, 72 to 75.9 and 76 Gy or greater) variable. Results: At a median 63-month followup multivariate analysis demonstrated that iPSA and radiotherapy (RP) dose were the most significant predictors of BF, followed by Gleason score and T stage. Perineural invasion was not an independent correlate of outcome. RT dose was significant in all iPSA groups (less than 10, 10 to 19.9 and 20 or greater ng/ml). Gleason score was significant when iPSA was less than 10 ng/ml. T stage was significant when iPSA was 20 ng/ml or greater and it was borderline when iPSA was 10 to 19.9 ng/ml (p = 0.08). Prognostic subgroups were derived from these results and tested for an effect of RT dose on univariate analysis. Radiation dose was not a correlate of BF in the most favorable (PSA less than 10 ng/ml and Gleason score 2 to 6) and the most unfavorable (PSA 20 ng/ml or greater and stage T3-T4) prognostic groups but it was otherwise an influential determinant of outcome. Conclusions: RT dose escalation to 76 Gy or greater improved patient outcome for all prognostic groups except those at the favorable and unfavorable extremes.

KW - Dose-response relationship, radiation

KW - Prostate

KW - Prostatic neoplasms

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=1542297823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542297823&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000111844.95024.74

DO - 10.1097/01.ju.0000111844.95024.74

M3 - Article

VL - 171

SP - 1132

EP - 1136

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -